GLP-1 Revolution: A Brief History

The incretin hormones were first discovered in 1932 by scientists studying the gut mucosa and glucose metabolism. In the 1970s, glucagon-like peptide-1 (GLP-1) was found to be produced in the enteroendocrine L cells of the small and large intestines in response to food intake. This 30-amino-acid peptide hormone plays a crucial role in regulating blood sugar levels by stimulating insulin secretion in the pancreas and slowing down stomach emptying. The discovery of incretins paved the way for the development of GLP-1 receptor agonists, a class of medications that imitate the actions of GLP-1 and can reduce hemoglobin A1c (HbA1c) by 1.5% and help people achieve total weight loss percentages of 10.9% after 6 months of use.

Skyrocketing popularity

GLP-1s have gained significant traction in the world of diabetes and weight loss management. Heralded by social media and Hollywood influencers, GLP-1 demand has created a monumental challenge in accessing these drugs. Coupled with supply chain shortages, high costs, and insurance coverage limitations, many patients were unable to utilize GLP-1s. As a result of this growing need, alternative strategies to ensure equitable access to these valuable treatments were paramount. Compounding offers a viable solution to this ever-growing problem.

Compounding benefits

There are several advantages of compounding GLP-1 medications. Tailored dosages can address individual patient needs that vary from standard commercial products. Additionally, compounding can reduce costs by eliminating the need for brand-name medications. Compounding can also provide personalized care for patients with specific needs or preferences. For example, compounding can address specific allergies and sensitivities by formulating GLP-1s with specific active pharmaceutical ingredients (APIs) devoid of excipients in commercially available options.

Increasing affordability

Compounding can increase the affordability of GLP-1s by offering cost-effective alternatives to brand-name options. Commercially available GLP-1s are significantly more expensive for several reasons. Research and development, clinical trials, regulatory approvals, patent protection, and advertising have driven the cost of GLP-1s to unprecedented levels. Compounded options provide the same biologically active component as brand names in a vial for subcutaneous self-injection. Compounded GLP-1s are available for a much lower price, providing an alternative for a wider segment of the population.

Supply solution

The use of GLP-1s has transformed the landscape of type 2 diabetes (T2DM) and weight loss management. As popularity has skyrocketed, the demand has created short supply and diminished accessibility. Equally challenging is the immense cost associated with name-brand offerings. Compounded versions offer better accessibility and affordability at a fraction of the cost. In addition, compounding can offer personalized formulations addressing individual allergies, sensitivities, and other specific needs. Talk to a healthcare provider or compound pharmacist to explore the many benefits of compounded GLP-1 medications.